The globally-dominant drugmaker is anticipating that findings from such a biotechnological research will help improve the science behind producing better drug candidates for cancer and other malignant diseases.
So far, scientific research has cleared the path for pharmaceutical companies struggling to boot out the “undruggable” tag from their products. For French pharmaceutical giant, Sanofi SA, the significance of science and R&D has escalated as the drug-making conglomerate continues to be riddled with challenges of detecting molecules that drive growth of diseases. Shape of these molecules were considered not suitable to be included in drugs, but Sanofi is expected to induce more profound pharmaceutical research on them, which will be accomplished through life science academics from reputable institutions in the US.
Sanofi’s scientific spin-off, Warp Drive Bio, has been active for a couple of years, and is now close to the release of its first drug candidate. In due course, the company has incurred challenging restraints while rendering its products marketable. Several CEOs from leading pharma companies have vetoed the commercialization of molecular drugs that have a potential of triggering the occurrence of malignant diseases such as cancer. Ergo, Sanofi, much like other drug companies, is not solely relying on its in-house scientists for determining new saleable drugs. With help of life science academics from Harvard, the company will be funding scientific research that will re-engineer drugs and treatments. The reported science project being conducted will enable Sanofi to understand diseases better than before.
Promising recommendations from biotech scientists will help pharmaceutical companies such as Sanofi gain a “patient protection” tag on their top-selling drugs. Dr. Verdine from Harvard University will be helming this world-class scientific study and use his groundbreaking experience on chemistry and biology to sketch out proteins that are crucial during incidence of a disease such as cancer. Till date, such protein molecules were considered undruggable due to their flat shape and scientists failed to link drugs to such proteins present inside a cell. Findings from this research have reportedly identified a naturally-occurring bacteria’s role in crossing cell walls and connecting drug molecules to flat proteins. With time, Sanofi will implement such key findings in production of cancer-curing drugs, eventually revolutionizing the healthcare industry as we know it.